VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis

Inclusion Criteria: * Male or female participant aged 18 years or older. * History of primarily plaque psoriasis for at least 6 months prior to the screening visit. * Has had stable psoriasis conditions for at least 3 months before screening. * Has moderate to severe plaque psoriasis as defined by a PASI score of ≥ 12 and an sPGA score of ≥ 3 at screening and Day 1. * Has plaque psoriasis covering ≥ 10% of the total BSA at screening and Day 1. * Deemed by the investigator to be eligible for phototherapy or systemic therapy. * Females of childbearing potential must agree to use a highly effective contraceptive method from at least 4 weeks prior to Day 1 until at least 4 weeks after the last dose of study product. Exclusion Criteria: * Female who is breastfeeding, pregnant, lactating, or who is planning to become pregnant during the study. * Has evidence of erythrodermic, pustular, predominantly inverse or guttate psoriasis, or drug-induced psoriasis. * History of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments. * Participant is known to have immune deficiency or is immunocompromised. * Has immune-mediated conditions commonly associated with psoriasis, such as psoriatic arthritis, active uveitis, inflammatory bowel disease, that currently require systemic treatment (including corticosteroids, immunosuppressants, or biologics). Note: Participants with immune-mediated conditions commonly associated with psoriasis that do not require systemic treatment may be included in the study. * Has used any topical medication that could affect psoriasis (including corticosteroids, retinoids, vitamin D analogues \[such as calcipotriol\], Janus kinase \[JAK\] inhibitors, or tar) within 2 weeks prior to Day 1. * Has used any systemic treatment that could affect psoriasis (including corticosteroids, oral retinoids, immunosuppressive medication, anakinra, methotrexate, cyclosporine, oral JAK inhibitors, or apremilast) within 4 weeks prior to Day 1. Note: Intranasal corticosteroids and inhaled corticosteroids are allowed. Eye and ear drops containing corticosteroids are also allowed. * Participant has received any ultraviolet B (UVB) phototherapy (including tanning beds) or excimer laser within 4 weeks prior to Day 1. * Participant has had psoralen and ultraviolet A (PUVA) treatment within 4 weeks prior to Day 1. * Participant has received treatment with an investigational or marketed TYK2 inhibitor.